Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. T. Schermuly, X. Tian, R. Dumitrascu, S. Pullamsetti, G. Kwapiszewska, N. Weissmann, H. Ghofrani, T. Dunkern, H. Tenor, R. Voswinckel, W. Klepetko, R. Paddenberg, W. Kummer, W. Seeger, F. Grimminger (Giessen, Konstanz, Germany; Vienna, Austria). Phosphodiesterase 1 upregulation in pulmonary arterial hypertension – target for anti-remodeling therapy. Eur Respir J 2006; 28: Suppl. 50, 987

Member's Comments

No comment yet.

Related content which might interest you: Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012 Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition Source: Eur Respir J 2013; 42: 869-870 Year: 2013 The use of combination therapy in pulmonary arterial hypertension: new developments Source: Eur Respir Rev 2009; 18: 148-153 Year: 2009 RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors Source: Eur Respir J, 50 (3) 1602425; 10.1183/13993003.02425-2016 Year: 2017 Predictors of response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors Source: International Congress 2016 – Clinic of pulmonary hypertension Year: 2016 HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Source: Eur Respir J 2005; 26: 858-863 Year: 2005 Leptin signalling system as a target for pulmonary arterial hypertension therapy Source: Eur Respir J 2015; 45: 1066-1080 Year: 2015 Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension Source: Eur Respir J, 56 (5) 2000522; 10.1183/13993003.00522-2020 Year: 2020 Survivin inhibition as a potential target for pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 Effects of iloprost and the phosphodiesterase inhibitor tolafentrine on pulmonary vascular remodelling in chronic experimental pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 20s Year: 2003 A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension Source: Eur Respir J, 51 (6) 1702638; 10.1183/13993003.02638-2017 Year: 2018 Comparison of acute hemodynamic effects of three different phosphodiesterase inhibitors in patients with pulmonary arterial hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 705s Year: 2004 Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension Source: Eur Respir J 2015; 46: 405-413 Year: 2015 Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2004; 24: 1007-1010 Year: 2004 Effects of a novel azaindole-based Rho-kinase inhibitor on hemodynamics and pulmonary vascular remodelling in experimental pulmonary hypertension Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009 Phosphodiesterase-type 3 inhibitor potentiates cAMP generation and antiproliferative effects of treprostinil in pulmonary arterial smooth muscle cells from patients with pulmonary hypertension Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension Year: 2010 Beta 3 adrenoceptor: a potential therapeutic target for pulmonary arterial hypertension Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020